AbbVie Inc (ABBV)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 6,240,000 | 13,468,000 | 12,982,000 | 3,392,000 | 8,426,000 |
| Revenue | US$ in thousands | 54,318,000 | 58,054,000 | 56,197,000 | 45,804,000 | 33,266,000 |
| Pretax margin | 11.49% | 23.20% | 23.10% | 7.41% | 25.33% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $6,240,000K ÷ $54,318,000K
= 11.49%
In reviewing Abbvie Inc's pretax margin over the past five years, we observe fluctuations in the company's profitability before accounting for taxes. The pretax margin declined significantly from 25.33% in 2019 to 7.42% in 2020, reflecting potential challenges or inefficiencies during that period. However, there was a notable recovery in 2021 and 2022 when the pretax margin reached 23.11% and 23.21%, respectively, indicating improved operational performance and cost management.
The pretax margin experienced a decrease to 11.51% in 2023, which might suggest a possible shift in the company's cost structure or revenue dynamics. Overall, the trend in the pretax margin of Abbvie Inc demonstrates variability in its profitability performance, highlighting the importance of consistent monitoring and strategic decision-making to sustain and enhance financial health.
Peer comparison
Dec 31, 2023